DUBLIN–(BUSINESS WIRE)–The “Biopharmaceutical Contract Development and Manufacturing Organization Market Forecast to 2033” has been added to ResearchAndMarkets.com’s offering.
The global biopharmaceutical contract development and manufacturing organization (CDMO) market is poised to experience significant growth, with market size projections soaring from USD 25.1 billion in 2024 to USD 56.6 billion by 2033, reflecting a CAGR of 9.55% between 2025 and 2033. This market expansion is driven by increasing demand for biologics, biosimilars, and advanced therapies.
The growing trend of outsourcing services among biopharmaceutical manufacturers, driven by large product pipelines and cost effectiveness, has become a major catalyst for this growth. Biopharmaceutical companies are increasingly focusing on biologics and biosimilars to cater to the demand for targeted, effective, and personalized therapies. These therapies not only offer higher efficacy and reduced side effects but also have the potential to address complex diseases, including cancer and autoimmune disorders.
The CDMO market has opened up new opportunities due to specialized CDMOs offering faster speed-to-market solutions and the rise in demand for blockbuster drugs, resulting in a robust pipeline for biologics and biosimilars. Advancements in biotechnology are further reducing production costs and risks, making biologics the focal point for clinical value and commercial potential.
Biopharmaceutical manufacturing is expected to emerge as one of the top revenue generators in the coming years. Though small molecules currently dominate the pharmaceutical industry, representing 90% of the drugs available, there is a noticeable shift towards the development of large, complex molecules known as biologics. This shift has fostered a need for external partnerships to manage advanced manufacturing processes, increasing reliance on CDMO services. According to the International Federation of Pharmaceutical Manufacturers & Associations, the biopharmaceutical R&D spending is projected to hit USD 213 million by 2025, driven by the escalating demand for biopharmaceutical products.
Global Biopharmaceutical CDMO Market Report Segmentation:
This comprehensive report forecasts revenue growth at global, regional, and country levels, analyzing key industry trends from 2021 to 2033. The report segments the CDMO market based on various parameters including:
- Type Outlook: API, Finished Drug Product
- Product Outlook: Biologics, Biosimilars
- Service Outlook: Contract Development, Upstream, Downstream, Contract Manufacturing, Packaging and Labelling, Regulatory Affairs, Logistics & Storage, Others
- Source Outlook: Mammalian, Microbial
- Workflow Outlook: Clinical, Commercial
- Therapeutic Area Outlook: Oncology, Infectious Diseases, Neurological Disorders, Cardiovascular Disease, Metabolic Disorders, Autoimmune Diseases, Respiratory Diseases, Ophthalmology, Gastrointestinal Disorders, Others
- End Use Outlook: Large Pharma & Biotech Companies, Small & Mid-sized Pharma & Biotech Companies, Academic Research & Government Institutes
- Regional Outlook: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Why You Should Buy This Report:
- Comprehensive Market Analysis: Gain insights into the market across key regions and segments.
- Competitive Landscape: Understand the market presence of leading players.
- Future Trends: Explore pivotal trends and drivers shaping the market’s future.
- Actionable Recommendations: Leverage insights to identify new revenue streams and strategize business decisions.
Report Deliverables:
- Market intelligence for effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Analyses of growth opportunities and trends
- Segment and regional revenue forecasts
- Competitive strategy and market share analysis
- Product innovation listings to stay competitive
Key Attributes
| Report Attribute | Details |
| No. of Pages | 120 |
| Forecast Period | 2024-2033 |
| Estimated Market Value (USD) in 2024 | $25.1 Billion |
| Forecasted Market Value (USD) by 2033 | $56.6 Billion |
| Compound Annual Growth Rate | 9.5% |
| Regions Covered | Global |
The companies profiled in this Biopharmaceutical Contract Development and Manufacturing Organization market report include:
- Lonza Group
- Thermo Fisher Scientific
- Catalent Pharma Solutions
- Samsung Biologics
- WuXi Biologics / WuXi AppTec
- Boehringer Ingelheim (Biopharma CDMO)
- Fujifilm Diosynth Biotechnologies
- Charles River Laboratories
- AGC Biologics
- Siegfried Holding
- Recipharm
- Millipore Sigma (Merck KGaA)
- Biocon Biologics
- Sandoz
- Rentschler Biopharma SE
For more information about this report visit https://www.researchandmarkets.com/r/1ey02q
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900